other material
confidence high
sentiment negative
materiality 0.60
Spyre SPY072 RA sub-study shows significant efficacy vs placebo but misses bar for RA monotherapy
Spyre Therapeutics, Inc.
- SPY072 Low Dose ΔDAS28-CRP -1.9 (p<0.05) vs placebo -1.3 at Week 12; High Dose ACR20 63% (nominal p<0.05) vs placebo 43%.
- Low Dose ACR50 38% (nominal p<0.05) vs placebo 19%; ACR70 4% vs 2%.
- Adverse events 27% active vs 36% placebo; one serious TEAE per arm, none drug-related; one death in placebo arm.
- Did not meet internal bar to prioritize SPY072 as monotherapy in RA; supports TL1A combo potential.
- PsA/axSpA topline on track Q4 2026; SPY072 + IL-17A/F HS readout late 2027/early 2028.